Tetrabenazine: For chorea associated with huntingtons disease

CNS Drugs

Volumn 25, Issue 12, 2011, Pages 1073-1085

  Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Huntingtons disease; Tetrabenazine

Indexed keywords

ALANINE AMINOTRANSFERASE; AMIODARONE; ASPARTATE AMINOTRANSFERASE; DIGOXIN; DOPAMINE; DULOXETINE; FLUOXETINE; MONOAMINE; PAROXETINE; PLACEBO; QUINIDINE; RESERPINE; SERTRALINE; TERBINAFINE; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORTER 2;

AGITATION; AKATHISIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY DISORDER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; CONTROLLED CLINICAL TRIAL (TOPIC); DELUSION; DEPRESSION; DIARRHEA; DROWSINESS; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; EPIGASTRIC PAIN; FALLING; FATIGUE; FIRST PASS EFFECT; HUMAN; HUNTINGTON CHOREA; HYPOTENSION; INSOMNIA; IRRITABILITY; LIVER DYSFUNCTION; MORNING DOSAGE; MULTICENTER STUDY (TOPIC); NAUSEA; NERVE ENDING; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PURPURA; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; RESTLESSNESS; SEDATION; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; TIC; TREATMENT OUTCOME; UNIFIED HUNTINGTON DISEASE RATING SCALE;

ANIMALS; CHOREA; CLINICAL TRIALS AS TOPIC; DOPAMINE; DOUBLE-BLIND METHOD; DRUG EVALUATION, PRECLINICAL; HUMANS; HUNTINGTON DISEASE; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 82555196456     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11208330-000000000-00000     Document Type: Article

References (51)

1. Krobitsch S, Kazantsev AG. Huntington's disease: from molecular basis to therapeutic advances. Int J Biochem Cell Biol 2011; 43 (1): 20-4
2. Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011; 10 (1): 83-98
3. Huntington's Disease Society of America. Lifting the veil of Huntington's disease recommendations to the field from the Huntington's Disease Peer Workgroup online. Available from URL: http://www.hdsa.org/images/con tent/1/1/11709.pdf Accessed 2011 Aug 4
4. Frank S, Jankovic J. Advances in the pharmacological management of Huntington's disease. Drugs 2010; 70 (5): 561-71
5. de Tommaso M, Serpino C, Sciruicchio V. Management of Huntington's disease: role of tetrabenazine. Ther Clin Risk Manag 2011; 7: 123-9
6. Novak MJU, Tabrizi SJ. Huntington's disease. BMJ 2010; 340: c3109
7. Paulsen JS, Nehl C, Ferneyhough K, et al. Depression and stages of Huntington's disease. J Neuropsychiatry Clin Neurosci 2005; 17 (4): 496-502 (Pubitemid 41790050)
8. Kirkwood SC, Su JL, Conneally M, et al. Progression of symptoms in the early and middle stages of Huntington disease. Arch Neurol 2001; 58 (2): 273-8 (Pubitemid 32163165)
9. van Duijn E, Kingma EM, van der Mast RC. Psychopathology in verified Huntington's disease gene carriers. J Neuropsychiatry Clin Neurosci 2007; 19 (4): 441-8 (Pubitemid 350156103)
10. Walker FO. Huntington's disease. Lancet 2007; 369: 218-28 (Pubitemid 46107685)
11. Paulsen JS, Hoth KF, Nehl C, et al. Critical periods of suicide risk in Huntington's disease. Am J Psychiatry 2005; 162 (4): 725-31 (Pubitemid 40489135)
12. Setter SM, Neumiller JJ, Dobbins EK, et al. Treatment of chorea associated with Huntington's disease: focus on tetra-benazine. Consult Pharm 2009; 24 (7): 524-37
13. Poon LH, Kang GA, Lee A J. Role of tetrabenazine for Huntington's disease-associated chorea. Ann Pharma-cother 2010; 44 (6): 1080-9
14. Mestre T, Ferreira J, Coelho MM, et al. Therapeutic interventions for symptomatic treatment in Huntington's disease (review). Cochrane Database Syst Rev 2009; 3: CD006456
15. Lundbeck Inc. US prescribing information: Xenazine® (tetrabenazine) tablets online. Available from URL: http://www.lundbeckinc.com/USA/products/CNS/ xenazine/usa- xen-pi.pdf Accessed 2011 Jul 20
16. Quinn GP, Shore PA, Brodie BB. Biochemical and pharmacological studies of RO I-9569 (tetrabenazine), a non-indole tranquilizing agent with reserpine-like effects. J Pharmacol Exp Ther 1959; 127: 103-9
17. Pettibone DJ, Totaro JA, Pflueger AB. Tetrabenazineinduced depletion of brain monoamines: characterization and interaction with selected antidepressants. Eur J Pharmacol 1984; 102(3-4): 425-30 (Pubitemid 14064081)
18. Mehvar R, Jamali F. Concentration-effect relationships of tetrabenazine and dihydrotetrabenazine in the rat. J Pharm Sci 1987; 76 (6): 461-5 (Pubitemid 17118285)
19. Scherman D. Dihydrotetrabenazine binding and monoamine uptake in mouse brain regions. J Neurochem 1986; 47: 331-9 (Pubitemid 16052845)
20. 3Hdihydrotetrabenazine. Proc Natl Acad Sci USA 1983; 80: 584-8 (Pubitemid 13174647)
21. 3H-histamine by the neuronal isoform of the vesicular monoamine transporter. J Mol Neurosci 1995; 6 (4): 277-87
22. Lane JD, Smith JE, Shea PA, et al. Neurochemical changes following the administration of depleters of biogenic monoamines. Life Sci 1976; 19 (11): 1663-7
23. Christmas AJ, Coulson CJ, Maxwell DR, et al. A comparison of the pharmacological and biochemical properties of substrate-selective monoamine oxidase inhibitors.\Br J Pharmac 1972; 45: 490-503
24. Bagchi SP. Differential interactions of phencyclidine with tetrabenazine and reserpine affecting intraneuronal dopamine. Biochem Pharmacol 1983; 32 (19): 2851-6 (Pubitemid 13013720)
25. Pettibone DJ, Pflueger AB, Totaro JA. Tetrabenazine-induced depletion of brain monoamines: mechanisms by which des-methylimipramine protects cortical norepinephrine. Eur J Pharmacol 1984; 102 (3-4): 431-6 (Pubitemid 14064082)
26. Thibaut F, Faucheux BA, Marquez J, et al. Regional distribution of monoamine vesicular uptake sites in the mes-encephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine. Brain Res 1995; 692: 233-43
27. Pearson SJ, Reynolds GP. Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease. Neuropharmacology 1988; 27 (7): 717-9
28. Tomlinson DR. The mode of action of tetrabenazine on peripheral noradrenergic nerves. Br J Pharmac 1977; 61: 339-44 (Pubitemid 8209161)
29. Kenney C, Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurotherline 2006; 6 (1): 7-17
30. Reches A, Burke RE, Kuhn CM, et al. Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain. J Pharmacol Exp Ther 1983; 225 (3): 515-21 (Pubitemid 13070863)
31. Login IS, Cronin MJ, MacLeod RM. Tetrabenazine has properties of a dopamine receptor antagonist. Ann Neurol 1982; 12: 257-62 (Pubitemid 12053032)
32. Kenney C, Hunter C, Davidson A, et al. Short-term effects of tetrabenazine on chorea associated with Huntington's disease. Mov Disord 2007; 22 (1): 10-3 (Pubitemid 46382667)
33. Wang H, Chen X, Li Y, et al. Tetrabenazine is neuroprotective in Huntington's disease mice. Mol Neurodegener-ation 2010; 5 (18)
34. Tang T-S, Chen X, Liu J, et al. Dopaminergic signaling and striatal neurodegeneration in Huntington's disease. J Neurosci 2007; 27 (30): 7899-910 (Pubitemid 47173323)
35. US FDA Peripheral and Central Nervous Systems Advisory Committee. Briefing Memo for December 6, 2007 PCNS AC meeting to discuss NDA 21-894, for the use of Xena-zine (tetrabenazine) in the treatment of the chorea of Huntington's Disease (HD) online. Available from URL: http://www.fda.gov/ohrms/ dockets/ac/07/briefing/2007-432 8b1-01-FDA.pdf Accessed 2011 Nov 7
36. Mehvar R, Jamali F, Watson MW, et al. Pharmacokinetics of tetrabenazine and its major metabolite in man and rat: bioavailability and dose dependency studies. Drug Metab Dispos 1987; 15 (2): 250-5 (Pubitemid 17056771)
37. Roberts MS, McLean S, Millingen KS, et al. The pharmacokinetics of tetrabenazine and its hydroxy metabolite in patients treated for involuntary movement disorders. Eur J Clin Pharmacol 1986; 29 (6): 703-8 (Pubitemid 16155744)
38. Schwartz DE, Bruderer H, Rieder J, et al. Metabolic studies of tetrabenazine, a psychotropic drug in animals and man. Biochem Pharmacol 1966; 15 (5): 645-55
39. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006; 66 (3): 366-72
40. Ferrara JM, MostileG,HunterC,etal. Effectoftetrabenazine on motor function in patients with Huntington disease abstract no. P05.021. 62nd Annual Meeting of the American Academy of Neurology; 2010 Sep 10-17; Toronto (ON)
41. Ondo WG, Tintner R, Thomas M, et al. Tetrabenazine treatment for Huntington's disease-associated chorea. Clin Neuropharmacol 2002; 25 (6): 300-2 (Pubitemid 36025267)
42. Brusa L, Orlacchio A, Moschella V, et al. Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine. Mov Disord 2009; 24 (1): 126-9
43. McLellan DL, Chalmers RJ, Johnson RH. A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea. Lancet 1974; 1 (7848): 104-7
44. Fasano A, Cadeddu F, Guidubaldi A, et al. The long-term effect of tetrabenazine in the management of Huntington disease. Clin Neuropharmacol 2008; 31 (6): 313-8
45. Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. Erratum appears in BMC Neurol 2011; 11: 18. BMC Neurol 2009; 9: 62
46. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997; 48 (2): 358-62 (Pubitemid 27087603)
47. Frank S, Ondo W, Fahn S, et al. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol 2008; 31 (3): 127-33 (Pubitemid 351787108)
48. Kingston D. Tetrabenazine for involuntary movement disorders. Med J Aust 1979; 1 (13): 628-30 (Pubitemid 10224909)
49. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996; 11 (2): 136-42
50. Biglan K, Eberly S, Auinger P, et al. Depressed mood, antidepressants, and tetrabenazine: results from the TETRA-HD study abstract. World Congress of Huntington's Disease; 2011 Sep 11-14; Melbourne (VIC)
51. Kenney C, Hunter C, Mejia N, et al. Is history of depression a contraindication to treatment with tetrabenazine? Clin Neuropharm 2006; 29 (5): 259-64 (Pubitemid 44439998)